The GABAA receptor alpha5 (GABAAα5) subunit is a critical component of GABA type A receptors, which mediate fast inhibitory neurotransmission in the central nervous system. These receptors are pentameric ligand-gated chloride channels composed of various subunit combinations (e.g., α, β, γ). The alpha5 subunit is predominantly expressed in the hippocampus, cortex, and olfactory bulb, where it forms receptors often incorporating β3 and γ2 subunits. GABAAα5-containing receptors are extrasynaptic or peri-synaptic, contributing to tonic inhibition and modulating neuronal excitability, synaptic plasticity, and cognitive processes such as learning and memory.
Antibodies targeting the GABAAα5 subunit are essential tools for studying its expression, localization, and functional roles. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research on receptor distribution in health and disease. Dysregulation of GABAAα5 has been implicated in neurological and psychiatric disorders, including Alzheimer’s disease, epilepsy, and anxiety. Selective alpha5-negative allosteric modulators are also explored for cognitive enhancement, as excessive alpha5-mediated inhibition may impair memory.
GABAAα5 antibodies thus support investigations into receptor biology, disease mechanisms, and therapeutic targeting, balancing specificity and validation to minimize cross-reactivity with other subunits. Their use helps clarify the subunit’s role in neural circuits and its potential as a drug target.